Alcon (ALC) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

$0.84

Estimate

$0.76

Surprise

+11.2%

Score at report (before → after)

5.3 → 5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Alcon (ALC) beat the $0.76 estimate with diluted EPS of $0.84 — a large 11.2% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.3/10) to Hold at 5.2/10 after the report — the engine's score fell despite the beat.

TrendMatrix currently rates ALC Hold at 5.2/10.

3 of the last 4 quarters beat the estimate; this quarter's +11.2% surprise compares with a +4.2% four-quarter average. Next scheduled report: 2026-11-10.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$70.50

Price target

$76.72

Stop

$68.37

Upside to target

+8.8%

Reward-to-risk

1.8:1

Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Instruments & Supplies

Market cap

$34.08B

P/E (fwd)

17.7

P/E (ttm)

55.1

52-week range

$61.84–$87.64

Off 52-week high

19.6%

RSI (14)

38

Volume vs avg

0.86×

Score today

5.2/10